RCS - Byotrol PLC - Launch of PROCESSUS® Instrument Decontamination

ByotrolAnnouncement

14/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231114:nRSN3145Ta&default-theme=true

RNS Number : 3145T  Byotrol PLC  14 November 2023

 

 

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

Launch of PROCESSUS® Instrument Decontamination System

 

Leading antimicrobial technology company Byotrol plc (AIM:BYOT) has today
announced the launch of PROCESSUS®, a 360-degree instrument decontamination
system, intended for the simple and effective reprocessing of instruments and
specialist equipment, in both animal and human healthcare organisations.

PROCESSUS® is the third launch of Byotrol's next-generation surface
disinfectant technology, which was first introduced in November 2022, under
Byotrol's market-leading ANIGENE brand and subsequently launched under the
CHEMGENE brand earlier this year.

 

Instrument decontamination refers to the process of making instruments and
equipment safe for use. This can be achieved by removing, deactivating, or
destroying contaminants, which can range from organic dirt and debris to
harmful pathogens, like viruses, bacteria, and fungi. While the pathogenic
threats to good patient care may differ slightly, the fundamental principles
of effective instrument decontamination remain the same in both human and
animal health environments.

 

The new PROCESSUS® brand debuts at the London Vet Show on the 16(th)
November, where Byotrol will be demonstrating the ease-of-use and flexibility
of the PROCESSUS® product range to animal health professionals from its key
commercial partners in veterinary, welfare and rehoming charities, and zoos
and wildlife organisations.

 

The PROCESSUS® Instrument Decontamination System incorporates enzymatic
cleaners, which are designed to remove organic matter prior to disinfection,
using a triple enzyme formulation which protects the integrity of
instruments.  Post-cleaning, PROCESSUS® Instrument Disinfectant kills
bacteria, yeasts, fungi, and viruses, including multi-drug resistant pathogens
as well as denaturing DNA / RNA.

 

Central to all Byotrol products, the PROCESSUS® Instrument Decontamination
System is supported by rigorous testing to the latest European efficacy test
methodology, specifically those required for instrument submersion. The
formulation is compatible with a wide range of equipment including
thermos-sensitive and fine lumened devices, nasal / fibre-optic scopes,
diagnostic and orthopedic equipment, and surgical and endontic instruments.

 

David Traynor, Interim CEO of Byotrol states:

 

"The launch of Byotrol's new PROCESSUS® Instrument Decontamination System
demonstrates another step forward in our plans to future-proof our portfolio
for EU and UK BPR regulatory approvals. It is the third in a series of
strategic portfolio updates, which strengthens our offering in both animal
health and human health markets."

 

For detailed information about the forthcoming PROCESSUS® Instrument
Decontamination range and supporting product documentation please visit our
commercial website, www.byotrol.com (http://www.byotrol.com) and follow the
company on LinkedIn.

 

For further information contact:

 

 Byotrol Plc
 Dr Trevor Francis, Non- Executive Chairman                                           +44 (0)1925 742 000
 David Traynor, Interim Chief Executive Officer                                       investorrelations@byotrol.com

 Chris Sedwell, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)                     +44 (0)20 7220 0500
 Geoff Nash / George Dollemore - Corporate Finance
 Nigel Birks / Harriet Ward - ECM

 Flagstaff Strategic and Investor Communications                                      +44 (0)20 7129 1474
 Tim Thompson/Andrea Seymour/Fergus Mellon                                            byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)

 

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and
control company, operating globally in animal health, human health, consumer
products and facilities management sectors. Byotrol develops and
commercialises innovative biocidal technologies and brands which provide
targeted protection against harmful pathogens.

 

For more information about Byotrol plc please visit byotrolplc.com
(https://byotrolplc.com/) and follow the company on LinkedIn
(https://www.linkedin.com/company/byotrol-plc/) .

For information on Byotrol products and customers please visit byotrol.com
(https://byotrol.com/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEFLFFSDFEA